Home Carrière Wetenschappelijk Onderzoek Publicaties 2018

Publicaties 2018

  • Van Der Luit CD, De Jong IR, Ebbens MM, Euser S, Verweij SL, van den Bemt PM, Luttikhuis HM, Becker ML. Frequency of occurrence of medication discrepancies and associated risk factors in cases of acute hospital admission. Pharm Pract (Granada). 2018 Oct-Dec;16(4):1301. doi: 10.18549/PharmPract.2018.04.1301.
  • Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Saf. 2018 Nov;41(11):1013-1022. doi: 10.1007/s40264-018-0684-9.
  • Bindraban AN, Rolvink J, Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML. Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. Int J Clin Pharm. 2018 Oct;40(5):1372-1379. doi: 10.1007/s11096-018-0692-y.
  • Out M, Becker ML, van Schaik RH, Lehert P, Stehouwer CD, Kooy A. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. Pharmacogenomics. 2018 Jun 1;19(8):715-726. doi: 10.2217/pgs-2018-0010.
  • Verweij SL, Schut NH, Zwartelé REAM, Becker ML. Nierfunctieverlies door gentamicine-implantatiesponzen. Ned Tijdschr Geneeskd. 2018;162: D2077
  • Bron JL, Verhart J, Sierevelt IN, De Vries D, Kingma HJ, Rademakers MV. No effect of double nerve block of the lateral cutaneous nerve and subcostal nerves in total hip arthroplasty. Acta Orthop. 2018 Jun;89(3):272-277. doi: 10.1080/17453674.2018.1437951.
  • Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018 Feb;74(2):183-191. doi: 10.1007/s00228-017-2381-5.
  • Berger FA, Monadian N, de Groot NMS, Santbergen B, van der Sijs H, Becker ML, Broers AEC, van Gelder T, van den Bemt PMLA. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors. Br J Clin Pharmacol. 2018 Feb;84(2):369-378. doi: 10.1111/bcp.13457.